Title
Incidence and clinical implication of trimethoprim/sulfamethoxazole susceptibility discrepancy between VITEK-2 and disc diffusion testing methods in Central Australia.
Author(s)
Abstract
OBJECTIVES: To investigate the incidence and clinical implications of the discrepancy of trimethoprim/sulfamethoxazole (TMP-SMX) susceptibility results produced by VITEK-2 and disc diffusion methods for Staphylococcus aureus.
METHODS: A retrospective matched-cohort study was conducted in a remote Australian hospital on S. aureus clinical isolates with reported TMP-SMX resistance by VITEK-2 from 1 August 2020 to 31 August 2023. Patient demographics, clinical information, TMP-SMX susceptibility by disc diffusion, TMP-SMX prescriptions, 30-day mortality, and 30-day presentation to the hospital emergency department (ED) were collected. Susceptibility data were compared between two susceptibility testing methods - VITEK-2 and disc diffusion. Clinical outcomes of patients with skin-and-soft-tissue infections (SSTI) caused by S. aureus with discrepant susceptibility (TMP-SMX-resistant by VITEK-2 but TMP-SMX-susceptible by disc diffusion) who were prescribed TMP-SMX were compared with a control group (patients treated with TMP-SMX for TMP-SMX-VITEK-2 susceptible S. aureus) in an approximate 1:1 ratio.
RESULTS: A total of 768 S. aureus isolates with reported TMP-SMX-resistance by VITEK-2 were identified and reassessed using disc diffusion. Only 13/768 (1.69%) were reported as TMP-SMX-resistant by disc diffusion. A total of 168/755 patients with discrepant susceptibility received a course of TMP-SMX; 102/168 (60.7%) were female, 154/168 (92.2%) were First Nations people. When comparing the discrepant susceptibility group with control, the number of 30-day ED presentations due to treatment failure of the original SSTI treated with TMP-SMX was not significantly different (6/168 versus 6/184, p=0.87).
CONCLUSIONS: We report a 98.3% (755/768) discrepancy rate of TMP-SMX resistance between VITEK-2 and disc diffusion methods in TMP-SMX-VITEK-2-resistant S. aureus isolates. There was no significant difference in outcomes between those with discrepant susceptibility and controls. This provides reassurance that TMP-SMX is effective in this setting and may significantly impact antimicrobial prescribing in settings with a high prevalence of methicillin-resistant S. aureus infections.
METHODS: A retrospective matched-cohort study was conducted in a remote Australian hospital on S. aureus clinical isolates with reported TMP-SMX resistance by VITEK-2 from 1 August 2020 to 31 August 2023. Patient demographics, clinical information, TMP-SMX susceptibility by disc diffusion, TMP-SMX prescriptions, 30-day mortality, and 30-day presentation to the hospital emergency department (ED) were collected. Susceptibility data were compared between two susceptibility testing methods - VITEK-2 and disc diffusion. Clinical outcomes of patients with skin-and-soft-tissue infections (SSTI) caused by S. aureus with discrepant susceptibility (TMP-SMX-resistant by VITEK-2 but TMP-SMX-susceptible by disc diffusion) who were prescribed TMP-SMX were compared with a control group (patients treated with TMP-SMX for TMP-SMX-VITEK-2 susceptible S. aureus) in an approximate 1:1 ratio.
RESULTS: A total of 768 S. aureus isolates with reported TMP-SMX-resistance by VITEK-2 were identified and reassessed using disc diffusion. Only 13/768 (1.69%) were reported as TMP-SMX-resistant by disc diffusion. A total of 168/755 patients with discrepant susceptibility received a course of TMP-SMX; 102/168 (60.7%) were female, 154/168 (92.2%) were First Nations people. When comparing the discrepant susceptibility group with control, the number of 30-day ED presentations due to treatment failure of the original SSTI treated with TMP-SMX was not significantly different (6/168 versus 6/184, p=0.87).
CONCLUSIONS: We report a 98.3% (755/768) discrepancy rate of TMP-SMX resistance between VITEK-2 and disc diffusion methods in TMP-SMX-VITEK-2-resistant S. aureus isolates. There was no significant difference in outcomes between those with discrepant susceptibility and controls. This provides reassurance that TMP-SMX is effective in this setting and may significantly impact antimicrobial prescribing in settings with a high prevalence of methicillin-resistant S. aureus infections.
Publication information
Clin Microbiol Infect . 2025 Dec 30:S1198-743X(25)00630-5. doi: 10.1016/j.cmi.2025.12.019. Online ahead of print.
Date Issued
2025-12-30
Type
Journal Article
Journal Title
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Permanent link to this record
Owning collection